Name

C-TPF

Alternate names

None

Primary Site

None

Histology

None

Radiation

None

Remarks

None

Drugs for C-TPF

Name

Alternate Names

5-Fluorouracil
5-Fluracil
Adrucil
Efudex
Fluoroplex
Fluracil
Fluril
Oracil
Ro 2-9757
WR-69596

Abbreviations

5-FU
5FU
FU

Category

Chemotherapy

Subcategory

Antimetabolite

NSC Number

019893
19893

Primary Site

Breast- adjuvant setting and advanced disease
colorectal- adjuvant setting and advanced disease
GI malignancies: anal, esophageal, gastric and pancreatic
Head and Neck cancer
Hepatoma
Ovarian cancer
Skin-Basal cell carcinoma (topical application)

Histology

None

Remarks

Fluorinated pyrimidine; antimetabolite. FDA approved uses on basal cell carcinoma, breast cancer, colorectal cancer, gastric cancer, and pancreatic cancer.

Note: Efudex cream be prescribed to treat AIN III. Code this as chemotherapy.

Coding

This drug should be coded

Name

Alternate Names

LIT-976
RP-56976
Taxotere

Abbreviations

None

Category

Chemotherapy

Subcategory

Taxane

NSC Number

628503

Primary Site

Breast
gastric
head & neck
non-small cell lung
ovarian
prostate cancer

Histology

None

Remarks

FDA approved for use on breast, prostate, stomach and NSCLC. Aventis Pharmaceuticals.

Coding

This drug should be coded

Name

Alternate Names

Cis-Platin
Cis-Platinum II#
Cisplatino (Spanish)
Cisplatinum
Cisplatyl
Neoplatin
Peyrone's chloride
Platinex
Platinol
Platinol-AQ
Platinol-AQ VHA Plus
Platinum

Abbreviations

CACP
CDDP
Cis-DDP
CPD
CPDC
CPDD
CPPD
DDP

Category

Chemotherapy

Subcategory

Alkylating agent
Platinum analog

NSC Number

119875

Primary Site

Bladder
ovarian
testicular cancer

Histology

None

Remarks

An alkylating antineoplastic agent. FDA approved uses on bladder, ovarian and testicular cancer; miscellaneous agent.

Coding

This drug should be coded

Name

Alternate Names

C 225
C-225
C225
Erbitux
IMC-C225

Abbreviations

None

Category

Biologic therapy (BRM, immunotherapy)

Subcategory

Monoclonal antibody, anti-EGFR antibody

NSC Number

714692

Primary Site

Breast
colorectal
head & neck
lung
ovarian
pancreatic cancer

Histology

None

Remarks

JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, cetuximab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code cetuximab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this drug as chemotherapy.

FDA approved colorectal 2004, head and neck 2006; orphan drug for pancreas
Anti-VEGFr chimeric monoclonal antibody.

Coding

This drug should be coded
Glossary